UK Markets closed

Siemens Aktiengesellschaft (SMAWF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
168.33+1.33 (+0.80%)
At close: 03:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous close167.00
Bid0.00 x 0
Ask0.00 x 0
Day's range163.96 - 168.45
52-week range135.50 - 177.58
Avg. volume3,669
Market cap136.155B
Beta (5Y monthly)1.10
PE ratio (TTM)19.29
EPS (TTM)8.72
Earnings dateN/A
Forward dividend & yield4.22 (2.57%)
Ex-dividend date04 Feb 2021
1y target estN/A
  • Reuters

    Siemens CEO Roland Busch gets 6.94 million euros for 2021

    Siemens Chief Executive Roland Busch picked up 6.94 million euros ($7.86 million) in compensation for the 2021 business year, his first year leading the engineering and technology company, the group's annual report, published on Thursday, showed. The 57-year-old, who took over from long-serving CEO Joe Kaeser in February, saw his compensation, including pension contributions, increase from the 5.05 million euros he received a year earlier as deputy CEO, the annual report said. Kaeser, who led Siemens from 2013, picked up 4.6 million euros for the year to end of Sept. 2021, the report said, down from 9.27 million euros he received a year earlier.

  • Reuters

    Siemens Energy, Andrade Gutierrez win $1.1 billion power plant order

    Siemens Energy and conglomerate Andrade Gutierrez have won 1 billion euro ($1.1 billion) contract to build a 1.7 gigawatt combined cycle power plant in Brazil, the German group said on Tuesday. The contract has been awarded by Gas Natural Acu (GNA), a joint venture of Siemens Energy, BP, Prumo Logistica and China's State Power Investment Corp, and is the follow-up order to a first plant, GNA I, which entered service in summer. Siemens Energy, which was spun off from Siemens AG last year, did not provide a breakdown of the contract value for GNA II, which will start operations in 2023.

  • Reuters

    Siemens Healthineers bets on Varian to boost growth

    Shares in Siemens Healthineers rose on Wednesday after the German health group said it expected its newly-acquired Varian business to grow faster than other divisions in the coming three years, boosting the group's revenue. Healthineers said revenue at Varian, the U.S. cancer treatment specialist it bought earlier this year in a $16.4 billion deal, should grow between 9% and 12% each year with operating return on sales rising to well over 20% until 2025. The company raised its synergy targets from the Varian takeover to more than 350 million euros ($396 million) by 2025, from a previous goal of 300 million euros.